Polycystic Ovary Syndrome (PCOS) Inhibitory Drug Screening from Selective Inositols
Abstract
Polycystic ovary syndrome (PCOS) is a heterogeneous ailment characterized by a combination of symptoms, including signs of androgen excess (hirsutism and/or hyperandrogenemia), ovarian dysfunction-oligo-ovulation and/or polycystic ovarian morphology (PCOM)), reproductive abnormalities, obesity, menstrual irregularity, type 2 diabetes (T2DM), hypertension, dyslipidemia, and depression. PubChem, enriched with 110 million chemicals, yielded 6327 inositol derivatives. Lipinski rule of five (MW up to 500 g/mol, H-bond donors 1–5, H-bond acceptors up to 10) criteria has been used for filtration of 582 compounds initial stage. Using escalating molecular weight, 101 molecules were selected from 582, to control this and rogen. To explore the possibility of androgen inhibition, various computational approaches, such as PASSprediction,protein-ligand interactions through molecular docking, chemical descriptors by DFT study, ADMET, bioavailability, and molecular dynamic (MD) simulation, were adopted by using the most accepted methods. Out of 101 inositol derivatives, 90 compounds were found to have more testosterone-inhibiting properties than ovulation-inhibiting or insulin-promoting properties in the PASS prediction investigation. Molecular docking analysis reveals a binding propensity for inositols of more than -7.4 kcal/mol between the androgen receptor protein (3RLJ) and inositols. Some of the most frequent bonded sites are shown to be at the MET:745 and ARG:752 amino acid residues,…
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.